Loading...

Article: The Role of the Pharma Industry in Superseding Outdated Medical Practices

2023-08-31T22:06:35+00:00Thought Leadership|

There has been and continues to be a surge in biotech innovation. But a pertinent question arises: how frequently are older, now outdated technologies phased out? Precision’s Ross Maclean, Phil Cyr and Ray Roth discuss the reluctance to abandon practices and technologies despite the availability of newer, better alternatives, and list how biopharma can lead the way.

READ MORE HERE!

White Paper: The Price is Right: Cell and Gene Therapy Approvals and Market Access in 2023

2023-10-31T13:27:22+00:00Thought Leadership|

Starting health economic evidence development and market access planning as early as possible in clinical development for a cell and gene therapy is important demonstrating the value to payers and health technology appraisal (HTA) organizations. In a dynamic regulatory and market access landscape, balancing the requirements of regulators and the expectations of payors can be challenging since there is no one-size-fits-all approach.

(more…)

Conference: CAR-TCR Summit, 2023

2023-10-31T13:30:32+00:00Events, Thought Leadership|

Precision will be at this year’s CAR-TCR Summit August 29 – September 1, 2023, in Boston, MA. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization of cell therapies.

Speaking Engagements
Detailed descriptions for each speaking engagement are included below.

  • Precision ADVANCE will hold a welcome reception on August 29, 2023, at 5:30 pm.
  • Project Farma will be facilitating a Manufacturing track panel discussion “Keys to Success for a Commercial – Ready Cell Therapy Facility” on August 30, 2023, 4:30 – 5:00 pm.
  • Precision ADVANCE will be facilitating an Early-Stage Clinical Strategy track panel discussion “Strategies for Successful Clinical Development of Cell Therapies” on August 30, 2023, 4:30 – 5:00 pm.
  • Precision ADVANCE will have a plenary speaking position “The Journey of Commercializing Cell Therapies” on August 31, 2023, 8:05 – 8:50 am.

Connect with our Advanced Therapy experts

  • Visit us at booth 90 in the exhibition area
  • Schedule in-person or virtual meetings with one of our experts
  • Attend our ADVANCE-sponsored Welcome Reception on August 29, 2023, at 5:30 PM ET

(more…)

White Paper: Cell and Gene Therapies: How High Can Prices Go?

2023-10-31T20:53:05+00:00Thought Leadership|

The concept of optimizing CGT value propositions begs the question of what is reasonable when it comes to breakthrough science and unprecedented therapeutic solutions. Can a $5 million price tag be justified? What about $10 million?

This white paper is based on a webinar convened by PRECISIONadvisors, focusing on cell and gene therapy (CGT) pricing. The webinar featured two in-house experts from the PRECISIONadvisors Global Pricing & Market Access practice: Richard Macaulay, Senior Vice President and David Carr, Senior Director.

(more…)

White Paper: The Future is Now: Cell and Gene Therapy Innovation, Challenges, and Perspectives

2023-11-06T18:37:00+00:00Thought Leadership|

Cell and gene therapies have the potential to revolutionize treatment of a wide range of diseases. With six new therapies approved in 2022, including the first allogeneic T-cell therapy, and at least as many slated for approval this year, the sector is poised for rapid growth. This innovation comes with challenges, though, and many consider 2023 to be a seminal year for establishing a strong foothold for advanced therapies in mainstream medicine.

(more…)

On Demand: The Future of Cell Therapy Development and Delivery

2023-11-06T18:45:01+00:00Events, Thought Leadership|

Sponsored by Precision ADVANCE, this Endpoints webinar convened leading advanced therapy experts to discuss the future of cell therapy development and delivery. This discussion was moderated by John Khoury: EVP (Project Farma), and included insights from Chris McDonald: Global Head of Tech Ops (Kite Pharma), Mark Frattini: CMO (Cellectis), Jason Foster: CEO & ED (Ori Biotech), and Phil Cyr: SVP (Precision Value & Health).

(more…)

Executive Summary: State of the Industry

2023-11-06T18:57:07+00:00Thought Leadership|

Tim Hunt, CEO of the Alliance for Regenerative Medicine (ARM), kicked off the event with a briefing on the state of the cell and gene therapy development landscape. With 475 members worldwide, ARM focuses on convening the sector, providing data and analysis, engaging with stakeholders, and enabling the development of advanced therapies. One of their key initiatives is modernizing healthcare systems to enable access to these novel therapeutics. Highlights of this briefing are provided in this summary.

(more…)

White Paper: mRNA Innovation Is Revolutionizing Disease Prevention

2023-11-09T12:57:05+00:00Thought Leadership|

The first FDA approved mRNA product was decades in the making, following many iterations throughout history the first mRNA vaccine in the US was brought to life. This achievement delivered aid to patients and healthcare providers during the most critical public health crisis in recent years. Since then, researchers have been operating at incredible speeds to develop more novel mRNA treatment options for patients, across many indications.

In this white paper, Anshul Mangal, President of Project Farma & Precision ADVANCE and Chad Salisbury, Senior Vice President of Project Farma (PF), discuss the mRNA revolution and its impact on the future of disease prevention and treatment.

(more…)

White Paper: “Preventative” Gene Therapies: Perspectives on Payer Access Challenges and Solutions

2023-11-09T13:32:33+00:00Thought Leadership|

Gene therapies offer hope for patients with severe genetic diseases by providing long-term benefits and even cures. However, the challenges of evaluating the long-term benefits of these therapies from a payer perspective are considerable. This white paper by PRECISIONadvisors highlights the shift of gene therapy research into more prevalent diseases, and outlines how manufacturers and payers can co—create evidence requirements and models to optimize launch success and sustainability.

(more…)

Load More Posts